XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Intangible Assets | 3 Months Ended
--- | ---
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets | Note 7: Intangible Assets Intangible assets as of March 30, 2024 and December 30, 2023 consist of the following (in $000’s):
| March 30, 2024 |  | December 30, 2023
Soin intangibles * | $ | 19,293 |  |  | $ | 19,293 |
Patents and domains | 4 |  |  | 4 |
Intangible assets | 19,297 |  |  | 19,297 |
Less accumulated amortization | (2,090) |  |  | (1,451) |
Total intangible assets | $ | 17,207 |  |  | $ | 17,846 |
*The Soin intangibles acquired by the Company consist of the following: 1.Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain; 2.Final formula for Naltrexone; and 3.Orphan drug designation as approved by the FDA. Intangible amortization expense was $639,000 and $363,000 for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration